The TRPC4 non-selective cation channel is widely expressed in the endothelium, where it generates Ca 2+ signals that participate in the endothelium-mediated vasodilatory response. This study sought to identify single-nucleotide polymorphisms (SNPs) in the TRPC4 gene that are associated with myocardial infarction (MI).
Introduction
The discovery of the TRP family of non-selective ion channels has facilitated our understanding of how animals detect diverse sensory inputs, but also how calcium signalling is generated in a broad range of cellular systems. 1 Different cellular, molecular, and animal model studies have highlighted the relevance of TRP channels in the vasculature whereby shaping Ca 2+ signals and modulating cell membrane potential play important roles in the regulation of vascular tone, remodelling, and integrity. 2 -6 However, from the genetic point of view, only a few reports have studied the relevance of TRP channels at the population level. For example, a single-nucleotide polymorphism (SNP) that generates a de novo binding site for nuclear factor kb in the promoter region of TRPC6 is associated with pulmonary hypertension; 7 an SNP-inducing loss of activity in TRPV4 has been associated with hyponatraemia; 8 and a loss-of-function SNP in TRPV1 has been associated with lower risk of respiratory symptoms in childhood asthma.
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Among the TRP channels, TRPC4 channel is widely expressed in the vasculature, 10 where it participates in the generation of intracellular Ca 2+ signals that regulate functions such as endothelial permeability, 11 smooth muscle proliferation, 12 and, of most importance to this study, endothelium-and nitric oxide (NO)-dependent vasorelaxation. 13 TRPC4 gating is not completely understood. It occurs downstream of both tyrosine kinase and G-protein-coupled receptor activation, 14, 15 with the participation of phosphatidylinositol 4,5-bisphosphate (PIP 2 ) inhibition only relevant to the long TRPC4a-splicing isoform. 16 Together, these observations make the TRPC4 channel an interesting target in evaluating contributors to the pathogenesis of human cardiovascular diseases. Coronary artery disease (CAD) is the leading cause of death in the developed world. The pathophysiology of myocardial infarction (MI), one of the clinical manifestations of CAD, involves a reduced blood supply to the myocardium. This blood supply is inversely related to the resistance in the myocardial vascular bed, which in turn depends on a calcium signal generated in the vascular smooth muscle (VSM). 17 Through modulation of the calcium signal, several VSM ion channels participate in setting the level of coronary arterial tone 18 -20 and a few of them have shown a genetic association with CAD, its treatment, or cardiovascular diseases that are risk factors for CAD. 21 -26 Endothelial cells modulate VSM tone following the release of vasomotor regulators or electrical coupling between endothelial cells and VSM, mechanisms in which endothelial ion channels are also involved, 27,28 including TRPC4. 13 MI is a complex disease whose heritability component 29 has been extensively reevaluated in the last few years by genome-wide association studies. 30 Novel loci have appeared, although in most cases, the functional connection between loci and phenotype remains to be elucidated. One exception seems to be an SNP in 1p13 that alters lipid metabolism by generating a new transcription factor-binding site. 31 Therefore, identification of functional genetic variants associated with MI is still necessary to improve our knowledge of the disease pathophysiology. The present study sought to identify SNPs in the TRPC4 that are associated with MI.
Methods

Gene polymorphism identification
The 11 exons of human TRPC4 were amplified from genomic DNA using PCR and analysed by direct sequencing in 50 healthy subjects. A novel SNP was found in exon 11 (A3104G, later included in SNP databases as rs73184536, NM_016179), corresponding to an isoleucine to valine mutation at position 957 of the protein (I957V). The TRPC4-I957V variant was identified by dideoxynucleotide sequencing (ABI PRISM BigDye Terminator 3.0; Applied Biosystems) and confirmed by sequencing of the second strand, using forward and reverse primers. Following the identification of the TRPC4-I957V polymorphism in the last exon of the TRPC4 gene by direct sequencing, this variant was analysed in every study participant. The DNA samples were analysed by TaqMan assay (ABI PRISM 7900HT; Applied Biosystems), using 5
′ -GGTGG AGGACACGGTTCCTA-3 ′ and 5 ′ -GTGACTGTGTCTGGGAGGTTT AG-3 ′ primers and FAM-ACTCTAGTGTAGACTATGAT and VIC-AG GACTCTAGTATAGACTATGAT probes for the V (G base) and I (A base) alleles, respectively. All participants gave written informed consent. The study conformed with the principles outlined in the Declaration of Helsinki and was approved by the Ethics Committee of the IMIM Institut de Recerca Hospital del Mar and Universitat Pompeu Fabra.
MI case -control study
We used a case -control design. Between January 1996 and December 2002, we recruited 1025 patients (188 women, 18.3%) with a first MI consecutively admitted to the only reference coronary unit in the catchment area in Girona, Spain. The 3899 participants from two cross-sectional studies in the same area served as controls and were judged free of angina or MI by medical records, physical examination, and electrocardiography. Standardized smoking and diabetes mellitus questionnaires and details of recruitment and measured variables are already described. 32 
Cell culture and transfection
Chinese hamster ovary (CHO) fibroblast cells (from the European Collection of Cell Cultures) were grown in Dulbecco's modified Eagle's medium supplemented with 10% foetal bovine serum. Culture media contained 1% streptomycin with penicillin. Cells were incubated at 378C in an atmosphere of 95% air -5% CO 2 . The CHO cells were transiently transfected with 0.3 mg pEGFP and 3 mg of either pcDNA3-hTRPC4b WT, pcDNA3-hTRPC4b I957V, or hTRPC4b Y959F using 8 equivalents of polyethylenimine (Fermentas MBI). Cells were used 24 -48 h after transfection. Human TRPC4-I957V mutant was generated by site-directed mutagenesis with primers 5
′ -GAAGAGGACTCTAGTGTAGACTATGA TCTAAACCTCC-3 ′ and 5
With the Quick Change w Site Directed Mutagenesis kit (Stratagene), TRPC4-Y959F double mutants were generated using primers 5
′ -GAA GAG GAC TCT AGT ATA GAC TTT GAT CTA AAC CTC CCA GAC-3 ′ and 5 ′ -GTC TGG GAG GTT TAG ATC AAA GTC TAT ACT AGA GTC CTC TTC-3 ′ for TRPC4-Ile-957 variant and primers 5
′ -GAA GAG GAC TCT AGT GTA GAC TTT GAT CTA AAC CTC CCA GAC-3 ′ and 5 ′ -GTC TGG GAG GTT TAG ATC AAA GTC TAT ACT AGA GTC CTC TTC-3 ′ for TRPC4-Val-957 variant (changes underlined). Mutants were verified by sequencing with ABiPrism 3.1 BigDye kit.
Patch-clamp recordings
Cells were plated in 35 mm plastic dishes and mounted on the stage of an Inverted Olympus IX70 microscope and the whole-cell currents were recorded with an Axon200A amplifier as described previously. 33 The bath solution contained either (in mM) 140 NaCl, 2. GTPgS, a G-protein-activating analogue of GTP; pH was adjusted to 7.4 with CsOH and 300 mOsm. Patch electrodes of 3 -5 MV were used. Membrane potential was held at 0 mV and ramps from 2110 to +100 mV (400 ms) were applied at a frequency of 0.2 Hz. Data were acquired at 10 kHz and low-pass filtered at 1 kHz. Single-channel recordings were carried out using a bath solution containing (in mM): 140 NaCl, 2.5 KCl, 0.5 EGTA, 0.5 MgCl 2 , 5 glucose, and 5 HEPES (pH 7.4 with Tris). The pipette solution contained (in mM) 120 CsCl, 10 HEPES, 12 glucose, and 0.5 MgCl 2 (pH 7.4 with Tris). Single-channel data were filtered at 2.5 kHz. Experiments were performed at room temperature. PP2, an inhibitor of the Src family of tyrosine kinases, and the negative control PP3 (Calbiochem, Merck4Biosciences) were used at 5 mM.
Measurement of intracellular [Ca
]
Cells were plated onto glass cover slips, loaded with 5 mM of Fura-2AM for 30 min at room temperature, washed out thoroughly, and bathed in an isotonic solution containing (in mM): 140 NaCl, 2. Figures 1 and 3 . All experiments were carried out at room temperature as described previously. 33 AquaCosmos software (Hamamatsu Photonics) was used to capture the fluorescence ratio at 505 nm, obtained following excitation at 340 and 380 nm. Images were computed every 5 s.
Molecular modelling of TRPC4 -Fyn kinase interaction
We used molecular modelling techniques to investigate how a single-point mutation at position 22 (aa 957) from Tyr-959 in the human TRPC4 channel could affect the interaction between a tyrosine kinase and the short sequence fragment containing the target tyrosine (see Supplementary material online for further details). We used the structural data available for the Fyn kinase that phosphorylates and modulates TRPC4. 
Statistical analysis
Deviation from the Hardy -Weinberg equilibrium was assessed using a 
Results
Genetic association studies
We identified an SNP in TRPC4 (A3104G, later renamed as rs73184536, NM_016179) corresponding to an isoleucine to valine mutation at position 957 of the protein (I957V). The frequency of the Val allele was 0.07 and the genotype frequencies in the representative random population sample of 3899 participants were 86.2, 13.4, and 0.4% for the IleIle, IleVal, and ValVal genotypes, respectively. The observed genotype frequencies fitted the Hardy-Weinberg equilibrium. The ValVal homozygote and IleVal heterozygote subjects were analysed together because of the low prevalence of the former.
We evaluated the association of TRPC4-I957V SNP with MI risk in a case-control study. The main characteristics of the sample are shown in Table 1 . We observed a statistically significant interaction (P ¼ 0.049) between the genetic variant and diabetes on MI risk. Multivariate analysis showed a protective effect of the 957V allele against MI risk only in diabetic subjects (adjusted OR ¼ 0.61; 95% CI, 0.40 -0.95, P ¼ 0.02; Table 2 ).
The association of TRPC4 with MI was also tested in the Wellcome Trust Case-Control Consortium (WTCCC), which included 1988 cases with CAD and 5380 healthy controls. The non-synonymous rs73184536 SNP (TRPC4-I957V) was not included in the chip used in this study. Therefore, we analysed SNPs within or near the TRPC4 chromosomic region (13q13:37.108-37.341). One SNP within the TRPC4 gene (rs7319926), belonging to the same linkage disequilibrium block as TRPC4-I957V, was associated with a lower prevalence of CAD (OR ¼ 0.87; CI, 0.81-0.94; P ¼ 0.0002).
Functional analysis of TRPC4-I957V variant
To evaluate the mechanism by which TRPC4-I957V might be protective against cardiovascular disease, we expressed and functionally tested wild-type (TRPC4-WT) and mutant channels (TRPC4-I957V) in CHO cells. Similar levels of expression were observed between TRPC4-WT and TRPC4-I957V channels in CHO cells (Supplementary material online, Figure S1 ). We measured cytosolic [Ca 2+ ] using the fura-2 sensor and cationic currents using the whole-cell and single-channel modes of the patch-clamp technique. TRPC4 is a non-selective cation channel that responds to the muscarinic agonist carbachol (Cch), epidermal growth factor, and other stimuli that use G-protein-mediated signalling.
14,15 Figure 1A shows representative Ca 2+ traces obtained from CHO cells transfected with control GFP, TRPC4-WT, or TRPC4-I957V and stimulated with 100 mM Cch using an add-back Ca 2+ protocol.
The first peak reflects Ca 2+ exit from the endoplasmic reticulum (ER) following the production of inositol trisphosphate (IP 3 ) and the activation of its receptor at the ER. TRPC4 genetic variant and cardiovascular disease with GFP, TRPC4-WT, and TRPC4-I957V ( Figure 1C and D) , consistent with the current view that TRPC4 is not a key player in store-operated calcium entry in the endothelium. 34 Mutant channel was also evaluated using electrophysiological techniques. Gating of TRPC4 currents with 88 mM GTPgS in transfected cells occurred within a few minutes following the whole-cell configuration and showed the characteristic TRPC4 double rectification current/voltage (I/V ) curves (Figure 2A and B) . In agreement with the [ Ca  2+ ] data, TRPC4-I957V channels showed higher response than TRPC4-WT channels. The mean channel response (at 2100 mV) is shown in Figure 4C . Interestingly, TRPC4-I957V protein appears to exert a dominant positive effect on the WT protein, as co-expression of both TRPC4-WT and TRPC4-I957V proteins in the same cell produces an increase in current density similar to that of TRPC4-I957V protein alone ( Figure 4C ). TRPC4 activity is regulated by tyrosine kinase phosphorylation, 15 a process that may be engaged via cross-activation secondary to muscarinic receptor activation. 35 Ile-957 resides close to a tyrosine (Tyr-959) that, when phosphorylated, regulates TRPC4 activity by inserting more channels into the plasma membrane. 15 In fact, singlechannel analysis using the cell-attached mode of the patch-clamp technique showed a three-fold increase in the number of active TRPC4-I957V channels compared with TRPC4-WT channels following carbachol stimulation (Figure 3) . The mean single-channel currents were similar to that reported previously for mouse TRPC4 (20) and no differences were observed between WT and I957V channels (2.7 + 0.2 and 2.8 + 0.2 pA for WT and mutant channel, respectively; n ¼ 4). This observation is consistent with a higher insertion of mutant channels into the membrane, although we cannot fully discard that mutant channels also presented an increased open probability, thereby facilitating the occurrence of multiple channels within a membrane patch. The presence of different amino acid residues within +5 positions from the target tyrosine modifies phosphorylation rates. 36 It might occur that I957V substitution affects channel phosphorylation and insertion into the membrane, which would offer an explanation for the higher activity of TRPC4-I957V. Prediction of the phosphorylation rate of the peptide
-D-L-N (corresponding to the TRPC4 sequence around Y959) using the NetPhos 2.0 server suggests an increase in the phosphorylation rate from 0.7 to 0.8 with the I957V change. Besides, molecular dynamics simulations over 1 ns, using the structural data available for the Fyn kinase that phosphorylates and modulates TRPC4 15 To further investigate at the molecular level the link between gain of channel function and tyrosine phosphorylation, we replaced TRPC4 genetic variant and cardiovascular disease Tyr-959 by the non-phosphorylated phenylalanine (Phe-959) in both TRPC4-WT and TRPC4-I957V. Y959F substitution decreased the activation of TRPC4-I957V to levels similar to those obtained with TRPC4-WT ( Figure 4A and B) . Mean responses are shown in Figure 4C . We also evaluated the sensitivity of TRPC4-WT and TRPC4-I957V channels to the tyrosine kinase inhibitor PP2, finding that PP2 reduced channel activity by 50% in TRPC4-WT, without a significant effect on TRPC4-I957V ( Figure 4D) . The non-active analog of PP2 (PP3) did not affect either WT or I957V channels (n ¼ 4, results not shown). Finally, the direct effect of I957V substitution on TRPC4 phosphorylation was evaluated (Supplementary material online, Figure S7 ). HEK293 cells transfected with FLAG-TRPC4-WT or FLAG-TRPC4-I957V were stimulated with epidermal growth factor and TRPC4 immunoprecipitated with an anti-FLAG antibody. Immunoprecipitated TRPC4 was assessed for tyrosine phosphorylation by immunoblotting with anti-phosphotyrosine antibody (PY20). Tyrosine phosphorylation of TRPC4-I957V showed a two-fold increase compared with TRPC4-WT.
Discussion
We have identified a genetic variation in TRPC4 (I957V) that links increased channel activity to a protective effect against MI. This gain of function determines higher Ca 2+ signals that may facilitate the generation of endothelium-and NO-dependent vasorelaxation mediated by TRPC4. 13 The enhanced channel activity of the genetic variant appears to be related to a firmer interaction of the channel with a regulatory tyrosine kinase that phosphorylates and regulates channel insertion into the membrane and its activity. This observation may also offer a clue to the interpretation of the protective effect of TRPC4-I957V against MI in diabetic patients, who present endothelial dysfunction typically associated with a reduced NO-dependent vasorelaxation. 37, 38 Therefore, it is conceivable that the association of the TRPC4-I957V polymorphism with protection against MI in diabetic patients might be due, at least in part, to the phosphorylationmediated gain of function of the mutated channel in the endothelium. The higher Ca 2+ signals generated by TRPC4-I957V may ultimately facilitate the generation of endothelium-and NO-dependent vasorelaxation, which would compensate the loss of tyrosine phosphorylation and subsequent reduction in NO-mediated vasodilatation described in diabetic vessels. 39 
Supplementary material
Supplementary material is available at Cardiovascular Research online.
